Regulation

Filter

Current filters:

None

Popular Filters

2125 to 2149 of 2536 results

NICE backs Roche RoActemra, but with PAS discount

22-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today recommended…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulationRoActemraRoche

Proposal to fund Lilly’s Effient in New Zealand

21-02-2012

PHARMAC, the Pharmaceutical Management Agency of New Zealand, is seeking feedback on a proposal to fund…

Asia-PacificEffientEli LillyPharmaceuticalPricingRegulation

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Germany’s IQWiG finds no added benefit for Novartis’ Rasilamlo

21-02-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether the drug…

Cardio-vascularEuropeNovartisPharmaceuticalRasilamloRegulation

Bayer to file for EU approval of aflibercept for central retinal vein occlusion

21-02-2012

German drug major Bayer (BAY: DE) says that it will file for European approval of its macular edema treatment…

afliberceptBayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulationResearch

EU approval for AstraZeneca thyroid cancer drug Caprelsa

21-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalRare diseasesRegulation

FDA approves first Cushing’s syndrome drug, Corcept’s Korlym

20-02-2012

Shares of USA-based Corcept Therapeutics (Nasdaq: CORT) leapt 62% to $4.90 in after-hours trading on…

Corcept TherapeuticsKorlymNorth AmericaNovartisPharmaceuticalRare diseasesRegulationSignifor

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

GlaxoSmithKline files for Tykerb/Tyverb with trastuzumab in USA and Europe

17-02-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has submitted regulatory applications…

EuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrastuzumabTykerbTyverb

GSK and Novartis withdraw EU extended use applications for Tyverb and Fluad, respectively

16-02-2012

The European Medicines Agency has been formally notified by UK pharma giant GlaxoSmithKline (LSE: GSK)…

EuropeFluadGlaxoSmithKlineNovartisOncologyPharmaceuticalRegulationTyverbVaccines

Quintiles expands in MENA pharma markets

16-02-2012

Biopharmaceutical services company Quintiles is extending its global footprint to provide commercial…

Dayarn PharmaMarkets & MarketingPharmaceuticalQuintilesRegulationRest of the World

Counterfeit Avastin found in USA by FDA

16-02-2012

The US Food and Drug Administration said yesterday that it is warning health care professionals and patients…

AvastinGenentechMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulationRoche

FDA now accepts Pfizer’s tafamidis NDA

16-02-2012

Having around a year ago issued a refuse to file letter (The Pharma Letter April 5, 2011), the US Food…

North AmericaPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

Karo Bio drops eprotirome and split up plans

15-02-2012

There was a double-dose of bad news for Sweden’s Karo Bio (STO: KARO), which this week said it would…

BiotechnologyCardio-vasculareprotiromeKaro BioMergers & AcquisitionsPharmaceuticalRegulation

US FDA priority review for Truvada for reducing HIV risk

15-02-2012

The US Food and Drug Administration has accepted the supplemental New Drug Application and granted a…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

PhRMA slams US President’s fiscal year 2013 budget plan

15-02-2012

Responding to US President Barack Obama’s fiscal year 2013 budget proposals, Pharmaceutical Research…

FinancialNorth AmericaPharmaceuticalPoliticsRegulation

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex

14-02-2012

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

EuropeInflammatory diseasesPfizerPharmaceuticalRegulationXiapex

FDA approves Merck & Co’s Zioptan

14-02-2012

The US Food and Drug Administration) has approved drug giant Merck & Co’s (NYSE: MRK) Zioptan (tafluprost…

Merck & CoNorth AmericaOphthalmicsPharmaceuticalRegulationSaflutanSanten PharmaceuticalsZioptan

Bayer’s Xarelto gets backing in Scotland

14-02-2012

German drug major Bayer’s (BAY: DE) oral anticoagulant Xarelto (rivaroxaban) has been accepted by…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

2125 to 2149 of 2536 results

Back to top